

Persistent COVID-19 negative report of a physician in Bangladesh living and visiting in Red listed country with some special precaution followed.

Sabrina Nahin¹ and Mohammad Ashraful Amin²

¹Green Life Medical College and Hospital

²North South University

December 22, 2021

Abstract

COVID-19 infections have been widespread in Bangladesh subsequently. We present the example of a 32-year-old Bangladeshi physician who worked in a hospital and was previously involved in collecting swabs for Covid19 patients, During the pandemic, he also traveled to a red-listed country and was continuously negative throughout the period.

Introduction

A COVID-19 catastrophic infection crisis, driven by the new coronavirus SARS-CoV-2, has presented a grave threat around the world. Bangladesh has also been affected by this viral infection(1). The World Health Organization labeled it a pandemic based to its parabolic spread in 213 nations (2). The disease is spread mostly through direct contact with infected patients' airborne droplets(3). To minimize the spread of disease, rapid recognition and accurate diagnosis have become critical. Several samples, such as nasopharyngeal or oropharyngeal swabs, nasopharyngeal or oropharyngeal aspirates or washes, bronchoalveolar lavage, phlegm, tracheal swab and blood, are collected from potential SARS-CoV-2 patients. The microbiological diagnosis is confirmed using the polymerase chain reaction (PCR)(4). SARS-CoV-2 RNA virus load in the upper airways was considerably higher throughout the first week and culminated at 4-6 days following onset of symptoms, when it could be sampled. In COVID-19 individuals, the sensitivity of nasopharyngeal scrapes was higher than that of oropharyngeal sweeps(5). But even though the research on COVID-19 is inconclusive, lower respiratory tract tissues include the highest viral loads in individuals with severe acute respiratory syndrome (SARS) and Middle East respiratory disease (MERS)(6, 7). Nucleic acid screening for severe acute respiratory syndrome coronavirus 2 had also detected benign patients with coronavirus infection (SARS-CoV-2)(8).In this report, we have presented a case of persistent COVID-19 negative report of physician in Bangladesh living and visiting in Red listed country.

Case report

32-year-old Muslim physician male with no substantial co-morbidities in his past. He worked as a doctor and resided in Dhaka, Bangladesh. The first instance COVID-19 was discovered on March 8, 2020 in Bangladesh. During this time, the government proclaimed "lockdown" across the country beginning March 23, 2020. He was participated in nasopharyngeal swab PCR for SARS-CoV-2 collection from patients in the cardiology department for research purposes three months later, on June 28, 2020. He had a nasopharyngeal swab PCR for SARS-CoV-2 before being collected and the results were negative. Before every time collecting the sample, he always takes aseptic precautions such as wearing PPI and drafting, medical masks, gloves, headgear, and work clothing, as well as using an ethanol-based hand sanitizer and washing his hands with

soap more than 20 times in a day. After completing the whole collection, he went back to the nasopharyngeal swab PCR for SARS-CoV-2 on August 11, 2020, which came out negative. In total, 36 people tested positive for SARS-CoV-2 throughout this collecting period. In the hospital, he had come into contact with COVID-19 cases. He had no experience of any illnesses like fever or other flu-like symptoms during the time he was collecting the sample. On September 24, 2020, her older brother was diagnosed with COVID-19 as a result of both PCR and HRCT involvement with whom he lives. In this period, he always looks after his brother. He went to the hospital and other workplaces with always a surgical mask and KN95. He always takes a shower after returning from outside activities and he washes his everyday clothes after each visit from outside. According to a WHO report released on December 27, 2020, Bangladesh has a total of 509,148 confirmed cases and 7,452 deaths. He then supplied a COVID-19 sample for travelling to India on January 28, 2021, which was similarly negative the next day. According to a WHO report dated January 25, 2020, India had 10,667,736 confirmed cases and 1,53,470 total deaths. He returned to Bangladesh on January 31, 2021, with a negative covid19 report. On March 10, 2021, he took another covid19 test in preparation for a trip for family reasons, which came back negative the next day. According to a WHO report dated March 8, 2021, Bangladesh had 550,330 illnesses and 8,462 deaths. According to a WHO report dated March 10, 2021, India has 11,244,786 confirmed cases and 157,930 total deaths. The covid19 test for repatriation to Bangladesh was negative on March 17, 2021. Since April 20, 2021, Bangladesh has been on the UK's and other some countries no-fly list. For entering India from Bangladesh on the dates of 17 April 2021, 30 August 2021, 09 October 2021, 28 October 2021, 30 October 2021, he had to undergo a nasopharyngeal swab PCR for SARS-CoV-2. He had to also again repeat the nasopharyngeal swab PCR for SARS-CoV-2 on the dates of 22 April 2021, 4 September 2021, and 5 November 2021 in order to return to Bangladesh from India. His total of nine sample tests all came back negative. During his stay in India, he constantly wears a double mask and keeps his hands sanitized. He also avoids crowds and prefers to go by private car whenever possible. In this period, some routine blood tests were performed, including a complete blood count, CRP, thyroid test, viral marker for hepatitis and HIV, with normal results. (Table 1). During this time, his relative was diagnosed with COVID-19 on June 24, 2021, and was later hospitalized. During this time, he regularly visited the hospital and interacted with other COVID-19 patients, as it was a COVID-19 specific hospital. He had no symptoms of COVID-19 throughout his entire travel experience. During this timeframe, he also had no additional medication history. He administered the first dose of Moderna COVID-19 Vaccine on July 19, 2021, and completed the second dosage on August 18, 2021.

From the commencement of COVID-19 2020 until November 2021, he took 14 Covid19 tests and was always negative, despite being in close proximity to COVID-19 positive cases and visiting one of the tops most cases identified and mortality countries in the world, Asia.

Discussion

We reported on a clinician in Bangladesh who had a persistent COVID-19 negative report while living in close proximity to known COVID-19 cases and visiting one of the countries with the highest death rates. The most prevalent method for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) testing is based on reverse transcriptase-polymerase chain reaction (RT-PCR) for the presence of viral RNA. The virus extraction or positive response of polymerase chain reaction (PCR) from phlegm, nasal sample, or throat swab is used to provide a clear diagnosis of corona virus disease 2019 (COVID-19)(9). Because the consequences of swab testing are affected by a variety of factors, along with the period of swab acquisition after the onset of symptoms, the location of the specimen, the shipping of the swab, and the procedures used in swab collection, physicians should not rule out COVID-19 in a widely speculated patient who has traveled to an epidemic zone(10). Thorough viral screening for SARS-CoV-2 infections could help ensure safe aircraft flight during the COVID-19 pandemic and slow the virus's wide adoption. Unfortunately, the efficiency of these test-and-travel procedures in reducing traveler risk of SARS-CoV-2 transmission of the disease at the community level is uncertain(11). Proven test-and-travel methods for SARS-CoV-2 infection, which include periodic viral diagnostics surrounding airline travel, can lower both passenger chance of infection and population-level SARS-CoV-2 transmission risk when traveling. The clinician performed 13 Covid19 tests (Figure 1) in order to detect for virus infection while traveling across nations. A negative RT-PCR

nasopharyngeal swab test does not rule out COVID-19. As a result, putting too much faith in test results could be harmful, and the demand for widespread testing could be exaggerated. Furthermore, avoiding attempting to test the many numbers, if not millions, of mild COVID-19 instances could save a significant quantity of personal protective equipment. Barrier protection and preemptive behavior, such as acquiring travel or having vaccinated before traveling overseas, is influenced by personal healthcare and well-being perspectives(12, 13). Masking, social dispersion, handwashing, cleansing of commonly handled items, better ventilation, self-isolation, and confinement are among the nonpharmaceutical measures advised to minimize SARS-CoV-2 transfer. Vaccines are the most effective way to avoid the SARS-CoV-2 outbreak. Numerous vaccinations are being developed in many countries using various approaches. The cornerstone of attempts to control the propagation of SARS-CoV-2 has been preventing transmission to the virus and, more recently, immunization against the virus(14). The percentage of false-negative SARS-CoV-2 results from patient respiratory samples varies between 1 and 30%(15). There is no screening test that offers 100% sensitivity and specificity. Despite the fact that the RT-PCR test seems to have become the best model for detecting SARS-CoV-2 virus, false-negative incidences have been observed. These false-negative results can occur for a variety of causes, including detecting either early or too late in the virus's pathogenic process, inefficient or defective sample collecting techniques, incorrect specimen aspects, low analytic sensitivity, low viral load, or viral shedding mutability. These false-negative findings could have major ramifications, opening the path for positive case aggregations to lead to adverse outcomes and increased transmission rates throughout the population. Because false negative RT-PCR results in cases of COVID-19 are not rare, researchers advocate collecting upper respiratory tract samples in the acute stage and lower respiratory samples or stool samples in the non-acute period(16). Doctors in India who are intensively examining the second wave state that bronchoalveolar lavage done on RT-PCR negative patients with COVID-19 symptoms produced COVID-19 positive results. According to a doctor quoted in the same source, 15 to 20% of COVID-19 patients come with the aforementioned issue, which is posing a problem for doctors(17). In another study, a scientist said that alterations in the SARS-CoV-2 virus may have enabled it to evade RT-PCR testing, and that the reagents must be re-configured immediately(18). Furthermore, epidemiology, background of exposure, and clinical signs such as fever or pulmonary disease should all be examined when establishing COVID-19. As a result, combining serum IgM/IgG antibody identification, nucleic acid testing, CT scan, and clinical characteristics increases COVID-19 accuracy rate. By falsely claiming that an infected individual does not have a disease, a false-negative test puts the entire society at danger. As a result, this individual may spread infection throughout the population. False negatives in group testing are far more dangerous than false positives in solo testing.

Conclusion

In summary, Medical professionals are at considerable risk of contracting in the COVID-19 outbreak, which is affecting the entire worldwide, due to its direct interaction with COVID-19 patients. In individuals with a diagnosis of substantial traveling or contact, COVID-19 cannot be counted out even if there are no pulmonary complaints. Whenever patients with suspected is significant, a lower respiratory specimen should be taken with proper precautions and a negative PCR test on upper respiratory samples may not be enough to establish out COVID-19. Asymptomatic travelers would benefit from routine test-and-travel techniques, which would lower the chance of disease from travelling during the pandemic.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Consent

The patient's written informed consent for publishing of this case report, as well as images, was acquired.

Author contributions

The article's first draft was written by MAA and SN. MAA and SN contributed to the literature review and manuscript preparation. All authors contributed to the final version by critically reviewing and editing drafts.

Ethical approval

The article is about a case study. As a result, our Ethics Committee's consent was not required.

Reference:

1. Rahman H, Fahad MAHI, Islam MN, Yasin A, Abdullah M, Al Mamun RA, et al. Covid19 in Bangladesh: Comparative Analysis of Infected Situation and Control Strategy.
2. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Bio Medica: Atenei Parmensis*. 2020;91(1):157.
3. Chavez S, Long B, Koyfman A, Liang SY. Coronavirus Disease (COVID-19): A primer for emergency physicians. *The American journal of emergency medicine*. 2021;44:220-9.
4. Organization WH. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 14 January 2020. World Health Organization; 2020.
5. Mawaddah A, Genden HS, Lum SG, Marina MB. Upper respiratory tract sampling in COVID-19. *The Malaysian journal of pathology*. 2020;42(1):23-35.
6. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, Albarrak A, et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. *The Journal of infectious diseases*. 2014;210(10):1590-4.
7. Tang P, Louie M, Richardson SE, Smieja M, Simor AE, Jamieson F, et al. Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. *Cmaj*. 2004;170(1):47-54.
8. Wu J, Liu X, Zhou D, Qiu G, Dai M, Yang Q, et al. Identification of RT-PCR-negative asymptomatic COVID-19 patients via serological testing. *Frontiers in public health*. 2020;8:267.
9. Feng H, Liu Y, Lv M, Zhong J. A case report of COVID-19 with false negative RT-PCR test: necessity of chest CT. *Japanese journal of radiology*. 2020;38(5):409-10.
10. Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonna A, Limsukon A, et al. Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19. *Journal of clinical microbiology*. 2020;58(5):e00297-20.
11. Kiang MV, Chin ET, Huynh BQ, Chapman LA, Rodríguez-Barraquer I, Greenhouse B, et al. Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study. *The Lancet Infectious Diseases*. 2021.
12. Chien PM, Sharifpour M, Ritchie BW, Watson B. Travelers' health risk perceptions and protective behavior: A psychological approach. *Journal of Travel Research*. 2017;56(6):744-59.
13. Sharon TR, Shahrabani S. Health precautions while traveling after COVID-19. *Journal of Tourism, Heritage & Services Marketing (JTHSM)*. 2021;7(2):68-73.
14. Gupta S, Smith L, Diakiw A. Avoidance of COVID-19 for Children and Adolescents and Isolation Precautions. *Pediatric Clinics*. 2021.
15. Kanji JN, Zelyas N, MacDonald C, Pabbaraju K, Khan MN, Prasad A, et al. False negative rate of COVID-19 PCR testing: a discordant testing analysis. *Virology journal*. 2021;18(1):1-6.

16. Jia X, Xiao L, Liu Y. False negative RT-PCR and false positive antibody tests—Concern and solutions in the diagnosis of COVID-19. *Journal of Infection*. 2021;82(3):414-51.

17. Jindal H, Jain S, Suvvari TK, Kutikuppala L, Rackimuthu S, Rocha ICN, et al. False-negative rt-pcr findings and double mutant variant as factors of an overwhelming second wave of covid-19 in India: an emerging global health disaster. *SN comprehensive clinical medicine*. 2021:1-6.

18. CT-scan confirms infection for several RT-PCR negative reports. *the times of india*. 2021.

Table and figure

Table 1. Laboratory parameters of the cases

Investigation	01-02-2021
HB%	14.6
Total Leucocyte count	8.3thou/uL
Lymphocytes	26 %
Neutrophil	69%
Platelet count	259 thou/Ul
T3	0.627 uIU/mL
T4	1.03 ng/dL
Hepatitis C antibody	Non-reactive
HBsAg	Non-reactive
HIV 4 TH Gen Assay	Non-reactive
VDRL	Non-reactive




Figure 1: Whole COVID-19 test sequence.

